These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 18035334)
1. Moderate degeneration of nigral neurons after repeated but not after single intrastriatal injections of low doses of 6-hydroxydopamine in mice. Richter F; Hamann M; Richter A Brain Res; 2008 Jan; 1188():148-56. PubMed ID: 18035334 [TBL] [Abstract][Full Text] [Related]
2. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889 [TBL] [Abstract][Full Text] [Related]
3. 6-Hydroxydopamine-induced lesions in a rat model of hemi-Parkinson's disease monitored by magnetic resonance imaging. Kondoh T; Bannai M; Nishino H; Torii K Exp Neurol; 2005 Mar; 192(1):194-202. PubMed ID: 15698634 [TBL] [Abstract][Full Text] [Related]
4. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. Fleming SM; Delville Y; Schallert T Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106 [TBL] [Abstract][Full Text] [Related]
5. Regulation of GAP-43 protein and mRNA in nigrostriatal dopaminergic neurons after the partial destruction of dopaminergic terminals with intrastriatal 6-hydroxydopamine. Iwata SI; Nomoto M; Fukuda T Synapse; 2001 Jan; 39(1):16-22. PubMed ID: 11071705 [TBL] [Abstract][Full Text] [Related]
6. Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion. Kikuchi Y; Yasuhara T; Agari T; Kondo A; Kuramoto S; Kameda M; Kadota T; Baba T; Tajiri N; Wang F; Tayra JT; Liang H; Miyoshi Y; Borlongan CV; Date I J Cell Physiol; 2011 May; 226(5):1390-8. PubMed ID: 20945350 [TBL] [Abstract][Full Text] [Related]
7. KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity. Väänänen AJ; Rauhala P; Tuominen RK; Liesi P J Neurosci Res; 2006 Aug; 84(3):655-65. PubMed ID: 16810683 [TBL] [Abstract][Full Text] [Related]
8. 6-hydroxydopamine lesions in anuran amphibians: a new model system for Parkinson's disease? Endepols H; Schul J; Gerhardt HC; Walkowiak W J Neurobiol; 2004 Sep; 60(4):395-410. PubMed ID: 15307145 [TBL] [Abstract][Full Text] [Related]
9. The footfault test as a screening tool in the 6-hydroxydopamine rat model of Parkinson's disease. Silvestrin RB; de Oliveira LF; Batassini C; Oliveira A; e Souza TM J Neurosci Methods; 2009 Mar; 177(2):317-21. PubMed ID: 19026686 [TBL] [Abstract][Full Text] [Related]
10. Intrastriatal injection of sonic hedgehog reduces behavioral impairment in a rat model of Parkinson's disease. Tsuboi K; Shults CW Exp Neurol; 2002 Jan; 173(1):95-104. PubMed ID: 11771942 [TBL] [Abstract][Full Text] [Related]
11. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987 [TBL] [Abstract][Full Text] [Related]
12. Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions. Truong L; Allbutt H; Kassiou M; Henderson JM Behav Brain Res; 2006 Apr; 169(1):1-9. PubMed ID: 16413939 [TBL] [Abstract][Full Text] [Related]
13. Neuroprotection in Parkinson models varies with toxin administration protocol. Anderson DW; Bradbury KA; Schneider JS Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378 [TBL] [Abstract][Full Text] [Related]
14. Effect of unilateral lesion of the nigrostriatal dopamine pathway on survival and neurochemistry of parafascicular nucleus neurons in the rat--evaluation of time-course and LGR8 expression. Sedaghat K; Finkelstein DI; Gundlach AL Brain Res; 2009 May; 1271():83-94. PubMed ID: 19328193 [TBL] [Abstract][Full Text] [Related]
15. Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats. Liu CQ; Chen Z; Liu FX; Hu DN; Luo JH Neuropharmacology; 2007 Dec; 53(7):832-41. PubMed ID: 17919665 [TBL] [Abstract][Full Text] [Related]
16. Biochemical alteration in cerebrospinal fluid precedes behavioral deficits in Parkinsonian rats induced by 6-hydroxydopamine. Lin JW; Shih CM; Chen YC; Lin CM; Tsai JT; Chiang YH; Shih R; Chiu PL; Hung KS; Yeh YS; Wei L; Chiu WT; Yang LY Surg Neurol; 2009 Dec; 72 Suppl 2():S55-65; discussion S65. PubMed ID: 19944827 [TBL] [Abstract][Full Text] [Related]
17. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice. Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184 [TBL] [Abstract][Full Text] [Related]
18. The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model. Yasuhara T; Shingo T; Muraoka K; wen Ji Y; Kameda M; Takeuchi A; Yano A; Nishio S; Matsui T; Miyoshi Y; Hamada H; Date I Brain Res; 2005 Mar; 1038(1):1-10. PubMed ID: 15748867 [TBL] [Abstract][Full Text] [Related]
19. Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies. Xu L; Sheng J; Tang Z; Wu X; Yu Y; Guo H; Shen Y; Zhou C; Paraoan L; Zhou J Neurobiol Dis; 2005 Feb; 18(1):152-65. PubMed ID: 15649706 [TBL] [Abstract][Full Text] [Related]
20. Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism. Brown AR; Hu B; Antle MC; Teskey GC Exp Neurol; 2009 Nov; 220(1):162-70. PubMed ID: 19703443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]